Non-alcoholic fatty liver disease resolution following sleeve gastrectomy
- 381 Downloads
Non-alcoholic fatty liver disease (NAFLD), a disease highly prevalent among the morbidly obese population, is one of the most common causes of chronic liver disease today. The purpose of this study was to observe the effect of laparoscopic sleeve gastrectomy (LSG) on the resolution of NAFLD.
A retrospective study was conducted of 84 patients diagnosed with NAFLD prior to undergoing LSG. The diagnosis of NAFLD was achieved based on transabdominal ultrasonographic imaging as per the 2012 joint guidelines for the diagnosis of NAFLD (American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology). The patients had follow-up anthropometric measurements and were re-evaluated with postoperative ultrasounds at different time frames to assess the resolution of the disease.
The median age of the patients was 44 (17–62), and 66.7 % were female. Average time since surgery was 3.3 years (range 1–5 years). The mean pre- and postoperative BMIs were 46.6 ± 7.8 and 33.0 ± 7.1, respectively, with a mean percent excess weight loss (%EWL) of 55.7 % ± 23.0. A total of 47 (56 %) patients showed complete resolution of NAFLD postoperatively. Multivariate analysis showed a significant resolution of NAFLD in patients achieving >50 % EWL (OR 10.1; p < 0.001) after controlling for age and sex.
Weight loss after LSG effectively resolved NAFLD in more than half of the obese patients in this study and can prove to be a useful tool in tackling the disease in the future.
KeywordsBariatric Sleeve gastrectomy Obesity NAFLD Metabolic surgery
The authors would like to thank all who have contributed to making this study possible, most notably Dr. Hind Almazeedi.
Compliance with ethical standards
The author Ardeshir Algooneh declares having no conflicts of interest or financial ties to disclose. The author Sulaiman Almazeedi declares having no conflicts of interest or financial ties to disclose. The author Salman Al-Sabah declares having no conflicts of interest or financial ties to disclose. The author Maha Ahmed declares having no conflicts of interest or financial ties to disclose. The author Feras Othman declares having no conflicts of interest or financial ties to disclose.
- 1.Lee D (2007) Obesity can lead to fatty liver a silent killer, editorial review Aug 2007. http://www.medicinenet.com/script/main/art.asp?articlekey=46582. Accessed 15 Feb 2015
- 12.American liver foundation. Non alcoholic fatty liver disease. January 2015. http://www.liverfoundation.org/abouttheliver/info/nafld. Accessed 20 Feb 2015
- 13.Sasaki A, Nitta H, Otsuka K (2014) Bariatric surgery and non-alcoholic fatty liver disease: current and potential future treatments. October 2014. http://journal.frontiersin.org/article/10.3389/fendo.2014.00164/full. Accessed 20 Feb 2015
- 14.Digestive Disease Week. Weight-loss surgery can reduce liver damage: study shows reversal of early-stage liver fibrosis after bariatric surgery. May 2014. http://www.ddw.org/news/articles/2014/05/06/weight-loss-surgery-can-reduce-liver-damage. Accessed 20 Feb 2015
- 15.Chalasani N, Younossi Z, Lavine J et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6):2005–2023CrossRefPubMedGoogle Scholar
- 16.Johnson B, Blackhurst D, Latham B et al (2013) Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg 216(4):545–556; discussion 556–558Google Scholar
- 19.Karcz W, Krawczykowski D, Kuesters S et al (2011) Influence of sleeve gastrectomy on NASH and type 2 diabetes mellitus. J Obes 765473Google Scholar
- 22.Chavez-Tapia N, Tellez-Avila F, Barrientos-Gutierrez T et al (2010) Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 20(1):CD007340Google Scholar